Bridget Hoyt

Real-world community study finds Enhertu in HER2-low metastatic breast cancer has trial-like discontinuation rates; ILD remains key toxicity.

A recent study reveals critical insights on disease progression and survival rates in patients with relapsed/refractory large B-cell lymphoma treated with bispecific antibodies.

Dexamethasone prophylaxis significantly reduces severe neurotoxicity in LBCL patients receiving axi-cel, enhancing safety without compromising efficacy.

A recent study reveals that Black patients with acute myeloid leukemia face significantly poorer survival rates compared to White patients, highlighting racial disparities in treatment outcomes.

New data reveals VCN-01 enhances survival and response rates in metastatic pancreatic cancer when combined with standard chemotherapy, promising future trials.

Patients with metastatic hormone-sensitive prostate cancer report stable health-related quality of life while receiving niraparib and abiraterone acetate in the AMPLITUDE trial.

Less inflammatory diets were linked to improved overall survival in stage III colon cancer, and physical activity showed synergistic benefits.

Proactive onco-coaching did not improve quality of life but was linked to better overall survival in patients with metastatic renal cell carcinoma.